Compare ANIX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | OCCI |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 120.2M |
| IPO Year | 2013 | N/A |
| Metric | ANIX | OCCI |
|---|---|---|
| Price | $2.55 | $2.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 88.7K | ★ 327.4K |
| Earning Date | 03-09-2026 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $2.62 |
| 52 Week High | $5.46 | $6.82 |
| Indicator | ANIX | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 41.37 |
| Support Level | N/A | $2.80 |
| Resistance Level | $3.10 | $3.07 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 13.49 | 61.11 |
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.